MedTrace Logo

Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer

NCT01436214 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-07-16

No results posted yet for this study

Summary

This study is a phase 1/2a, open label, dose escalation and safety study of APC-100 (2,2,5,7,8-Pentamethyl-6-chromanol) in men with advanced prostate cancer.

Conditions

Interventions

DRUG

APC-100

Daily oral, dose escalation, 28-day cycle(s)

Sponsors & Collaborators

  • Adamis Pharmaceuticals Corporation

    lead INDUSTRY

Principal Investigators

  • Elisabeth I Heath, MD · Wayne State University

  • Jeremy Cetnar, MD · University of Wisconsin, Madison

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2016-08-31
Completion
2017-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01436214 on ClinicalTrials.gov